BMEA - NASDAQ
Biomea Fusion, Inc.
$1.38
+6.2%Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
At a Glance
Live Snapshotbmea
Operating Expenses
Last Annual Value
79.90M
3-Year CAGR
-2%
5-Year CAGR
73%
10-Year CAGR
52%
Biomea Fusion, Inc. Competitors Analysis of Operating Expenses
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Biomea Fusion, Inc. NASDAQ:BMEA | 79.90M | -14.1% | 13.9% | N/A | |
 Fractyl Health, Inc. Common Stock NASDAQ:GUTS | 95.69M | 23.4% | 21.0% | N/A | |
 Immunic, Inc. NASDAQ:IMUX | 103.23M | 1.3% | 2.4% | 9.6% | |
 PMV Pharmaceuticals, Inc. NASDAQ:PMVP | 86.21M | 3.0% | 8.6% | N/A | |
 Adicet Bio, Inc. NASDAQ:ACET | 115.73M | -8.7% | 10.2% | 220.9% | |
 aTyr Pharma, Inc. NASDAQ:ATYR | 76.26M | 11.3% | 18.4% | 2.7% | |
 Pliant Therapeutics, Inc. NASDAQ:PLRX | 148.38M | -7.2% | 7.1% | N/A | |
 Surrozen, Inc. NASDAQ:SRZN | 45.03M | 34.4% | -2.5% | N/A | |
 Zentalis Pharmaceuticals, Inc. NASDAQ:ZNTL | 145.01M | -21.5% | -7.7% | N/A | |
 Spruce Biosciences, Inc. NASDAQ:SPRB | 36.51M | -16.2% | -2.8% | N/A | |
 Adverum Biotechnologies, Inc. NASDAQ:ADVM | 140.16M | 1.9% | -1.8% | 9.6% |
Biomea Fusion, Inc. Fair Value Envelope
Related Guides
Continue your BMEA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.